# Lymphocyte Therapy in Treating Patients With Kidney Cancer

> **NCT00002589** · PHASE2 · UNKNOWN · sponsor: **National Cancer Institute (NCI)** · enrollment: 90 (estimated)

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** muromonab-CD3
- **BIOLOGICAL:** therapeutic autologous lymphocytes
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00002589
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1994-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2013-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002589, "Lymphocyte Therapy in Treating Patients With Kidney Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00002589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*